NCT06936839View on ClinicalTrials.gov

Optimal ECMO Flow in the Critical Phase of Cardiogenic Shock to Optimize Peripheral Organ Perfusion and Myocardial Stress

Not yet recruitingOBSERVATIONAL
Enrollment

55

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions
Cardiogenic Shock
Interventions
OTHER

Obversation

Observing the optimal flow rate to reduce left ventricular stress and enhance peripheral organ perfusion during ramp tests (conducted at QECMO levels of 100%, 75%, 50%, and 25%, provided that SVO₂ remains \>55% and NIRS rSO₂ remains \>50%)

Trial Locations (1)

34090

Montpellier University Hospital, Montpellier

All Listed Sponsors
lead

University Hospital, Montpellier

OTHER

NCT06936839 - Optimal ECMO Flow in the Critical Phase of Cardiogenic Shock to Optimize Peripheral Organ Perfusion and Myocardial Stress | Biotech Hunter | Biotech Hunter